Biotechnological company BIOCAD has signed an agreement with a scientific center “Vector” on joint work on a vaccine based on the rVSV against COVID-19. The process of vaccine development has entered the final stage, the vaccine showed promise in tests on laboratory animals, including non human primates.
Under the agreement, biotechnology company BIOCAD bears the costs and organization of clinical trials rVSV vaccine, development of technology of production of preparation and production. Now to work on the vaccines allocated to three research groups, which employ more than 80 people of different specializations: genetic engineering and Virology to chemistry and bioinformatics.
“We have long been in scientific collaboration with Novosibirsk “Vector”, — said Dmitry Morozov, General Director of the biotechnological company BIOCAD, and now act as an industrial partner of the project on the development of the rVSV vaccine. We are pleased to provide our partners with industrial production, when will the clinical studies. In my opinion, today we should unite their intellectual efforts.”
Currently BIOCAD is working on developing mRNA-vaccine against coronavirus (SARS-CoV-2). Development will be based on the previous work to create oncovin. In late March the company agreed with the Ministry of healthcare of RF and the program of preclinical and first-phase clinical development of vaccines against coronavirus. The beginning of clinical trials is expected in 4-5 months.